All Stories

  1. Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection
  2. Reply
  3. Plasma thrombospondin 1 as a predictor of postoperative liver dysfunction
  4. Role of platelets in systemic tissue protection after remote ischemic preconditioning
  5. KRASstatus and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab
  6. 199. To be a principal investigator in clinical trials
  7. Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab
  8. Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients
  9. Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma
  10. The role of conversion chemotherapy in initially non-optimal resectable liver metastases
  11. W1882 Monitoring of Angiogenic Factors Cannot Replace Tumor Marker Analysis in Bevacizumab-Based Cancer Therapy
  12. Colorectal Cancer Liver Metastases: Neoadjuvant Therapy with Bevacizumab
  13. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases
  14. Influence of Hepatic Resection Margin on Recurrence and Survival in Intrahepatic Cholangiocarcinoma
  15. In Reply
  16. Using bevacizumab and cetuximab before liver surgery
  17. Patterns of hepatotoxicity after chemotherapy for colorectal cancer metastases: Effect of bevacizumab
  18. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases
  19. Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer
  20. Neoadjuvant Therapy With Bevacizumab
  21. Interdisciplinary management of colorectal cancer liver metastases
  22. Anforderungen der Chirurgie an die bildgebende Diagnostik